Xencor (XNCR) Non-Current Deferred Tax Liability (2016)
Xencor (XNCR) posted quarterly Non-Current Deferred Tax Liability of $65000.0 for Q4 2016, down 83.75% quarter-over-quarter from $400000.0 in Q3 2016.
Powered by 
Analysis
Xencor (XNCR) Non-Current Deferred Tax Liability (2016) Analysis & Trends
Xencor (XNCR) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $65000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Non-Current Deferred Tax Liability changed N/A year-over-year to $65000.0; the TTM figure through Dec 2016 stood at $65000.0 (changed N/A YoY), while the FY2016 annual figure was $65000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability eased to $65000.0 in Q4 2016 per XNCR's latest filing, from $400000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.8 million in Q2 2016 and bottomed at $65000.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 65,000.00 |
| Sep 30, 2016 | 400,000.00 |
| Jun 30, 2016 | 1.78 Mn |